Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 – 2026

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 – 2026

Chronic obstructive pulmonary disease (COPD) presents itself with mild, moderate, and severe symptoms. Treatment of chronic obstructive pulmonary disease (COPD) involves stepwise non-pharmacological and pharmacological interventions. Non-pharmacological interventions include risk reduction (smoking cessation) and preventing and treating co-morbidities (cardiovascular disease, anxiety, depression, and others). Pharmacological interventions include prescribing short acting bronchodilators, long acting bronchodilators, and others.

Market Dynamics

Factors such as awareness initiatives by organizations, increasing prevalence of COPD, and product launches is supporting the global chronic obstructive pulmonary disease (COPD) treatment market growth. For instance, in May 2019, Boehringer Ingelheim and Optimum Patient Care announced the creation of a new patient registry, APEX COPD, to better understand COPD and how it can be typically treated in primary care offices. Such initiatives by industry players are expected to boost global chronic obstructive pulmonary disease (COPD) treatment market over the forecast period. Moreover, pipeline for respiratory diseases and mainly COPD has several potential medications, which is expected to drive global chronic obstructive pulmonary disease (COPD) treatment market growth.

Key features of the study:

• This report provides in-depth analysis of global chronic obstructive pulmonary disease (COPD) treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018–2026), considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key companies covered as a part of this study include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA
• Insights from this report would allow marketers and management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global chronic obstructive pulmonary disease (COPD) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation:

• Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class:
• Bronchodilators
• Beta 2-Agonists
• Anticholinergics
• Theophyllines
• Phosphodiesterase Type 4 Inhibitors
• Steroids
• Others
• Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration:
• Oral
• Inhalation
• Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region:
• North America
• By Drug Class:
• Bronchodilators
• Beta 2-Agonists
• Anticholinergics
• Theophyllines
• Phosphodiesterase Type 4 Inhibitors
• Steroids
• Others
• By Route of Administration:
• Oral
• Inhalation
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• U.S.
• Canada
• Europe
• By Drug Class:
• Bronchodilators
• Beta 2-Agonists
• Anticholinergics
• Theophyllines
• Phosphodiesterase Type 4 Inhibitors
• Steroids
• Others
• By Route of Administration:
• Oral
• Inhalation
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Drug Class:
• Bronchodilators
• Beta 2-Agonists
• Anticholinergics
• Theophyllines
• Phosphodiesterase Type 4 Inhibitors
• Steroids
• Others
• By Route of Administration:
• Oral
• Inhalation
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• By Drug Class:
• Bronchodilators
• Beta 2-Agonists
• Anticholinergics
• Theophyllines
• Phosphodiesterase Type 4 Inhibitors
• Steroids
• Others
• By Route of Administration:
• Oral
• Inhalation
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East
• By Drug Class:
• Bronchodilators
• Beta 2-Agonists
• Anticholinergics
• Theophyllines
• Phosphodiesterase Type 4 Inhibitors
• Steroids
• Others
• By Route of Administration:
• Oral
• Inhalation
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Drug Class:
• Bronchodilators
• Beta 2-Agonists
• Anticholinergics
• Theophyllines
• Phosphodiesterase Type 4 Inhibitors
• Steroids
• Others
• By Route of Administration:
• Oral
• Inhalation
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country/Region:
• Central Africa
• South Africa
• North Africa
• Company Profiles
• AstraZeneca Plc*
• Company Overview
• Product Portfolio
• Financial Performance
• Key Strategies
• Recent Developments
• Orion Corporation
• Mylan N.V.
• Boehringer Ingelheim
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc
• Novartis AG
• Sunovion Pharmaceuticals, Inc.
• CHIESI Farmaceutici SpA

“*” marked represents similar segmentation in other categories in the respective section.